Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) is trending, with shares up 5% in the past month, despite its industry losing 1.2%. While the current quarter is expected to show a loss of $0.12 per share, the current fiscal year's consensus earnings estimate points to a +265% change from the prior year, though the next fiscal year is projected to decline -80.1%. Currently, Novavax holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market, and a Value Style Score of B, indicating it may be trading at a discount to its peers.

Analysis

Novavax (NVAX) shares have demonstrated a 5% return over the past month, marginally underperforming the Zacks S&P 500 composite's +5.3% gain but significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which experienced a 1.2% loss. The company faces a mixed near-term outlook: a projected loss of $0.12 per share for the current quarter represents a -112.1% year-over-year decline, with the Zacks Consensus Estimate for this period having shifted downwards by -280.8% in the last 30 days. However, for the current fiscal year, a strong earnings rebound is anticipated, with the consensus estimate of $2.03 per share indicating a +265% increase from the prior year, supported by a +140.7% upward revision in the last 30 days. This growth trajectory is not expected to continue into the next fiscal year, where earnings are forecasted to decrease by -80.1% to $0.40, despite a recent +10.6% upward estimate revision. Revenue forecasts exhibit similar volatility, with an expected -68.6% year-over-year contraction to $130.5 million in the current quarter, followed by a +38.1% annual increase to $942.33 million for the current fiscal year, and a subsequent -45.2% decline to $516.45 million in the next fiscal year. Novavax's most recent reported quarter showed robust performance, with revenues of $666.66 million (+610.3% YoY) and EPS of $2.93, surpassing consensus estimates by +215.04% and +312.68%, respectively. The company has a history of exceeding consensus EPS and revenue estimates three times over the last four quarters. Novavax currently holds a Zacks Rank #3 (Hold) and a Zacks Value Style Score of B, suggesting it may be trading at a discount compared to its peers.

Key Decisions for Investors

• Given the Zacks Rank #3 (Hold) and the contrasting short-term and medium-term earnings projections, investors should closely monitor upcoming earnings announcements and future estimate revisions before making significant portfolio adjustments.
• The substantial positive revision for current fiscal year earnings and strong recent performance offer potential upside, but this must be weighed against the projected significant downturn in both earnings and revenue for the next fiscal year.
• While the stock's 'B' Value Style Score indicates potential undervaluation relative to peers, the inherent volatility in financial forecasts warrants a cautious approach, particularly concerning the long-term growth sustainability beyond the current fiscal year.